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A B S T R A C T
Neointimal hyperplasia is a product of VSMC replication and consequent accumulation within the blood vessel
wall. In this study, we determined whether inhibition of protein kinase CK2 and the resultant stabilisation of
proline-rich homeodomain (PRH) could suppress VSMC proliferation. Both silencing and pharmacological in-
hibition of CK2 with K66 antagonised replication of isolated VSMCs. SiRNA-induced knockdown as well as
ectopic overexpression of proline-rich homeodomain indicated that PRH disrupts cell cycle progression.
Mutation of CK2 phosphorylation sites Ser163 and Ser177 within the PRH homeodomain enabled prolonged cell
cycle arrest by PRH. Concomitant knockdown of PRH and inhibition of CK2 with K66 indicated that the anti-
proliferative action of K66 required the presence of PRH. Both K66 and adenovirus-mediated gene transfer of
S163C:S177C PRH impaired neointima formation in human saphenous vein organ cultures. Importantly, neither
intervention had notable eﬀects on cell cycle progression, cell survival or migration in cultured endothelial cells.
1. Introduction
Vessel occlusion following neointima development restricts the
therapeutic potential of peripheral and coronary artery bypass grafts,
and percutaneous coronary interventions. Accumulation of vascular
smooth muscle cells (VSMCs) within the neointimal compartment
greatly facilitates the formation of restenotic lesions via both con-
tributing to its occlusive mass and serving as a foundation for super-
imposed, accelerated atherosclerosis [1,2]. Intervening with mod-
ulators of VSMC proliferation is hence considered a pragmatic approach
in designing preventative therapies against vein graft degeneration and
in-stent restenosis.
Protein kinase CK2 is a ubiquitously expressed and highly pleio-
tropic enzyme implicated in a diverse range of cellular functions in-
cluding such indices as cell cycle progression, viability and motility [3].
Aberrant activity has predictably been associated with malignant
transformation and aggressive tumour growth, with T-cell lymphomas
[4], non-small cell lung cancer [5], prostate cancer [6], and tumors of
the head, neck, mammary gland and kidney [7–9] being documented
examples. Emodin, DRB, DDZ and TBB, both naturally derived and
synthetic inhibitors of CK2, have been reported to induce cell cycle
arrest in isolated VSMCs [10–12], though in consideration of the pro-
miscuity of these compounds this action could not be solely ascribed to
suppression of CK2 activity.
The proline-rich homeodomain (PRH), also referred to as haema-
topoietically expressed homeobox (Hex/Hhex), is a multifunctional
transcription factor critical for embryonic and tissue development -
notably of the haematopoietic and vascular lineages [13–15]. PRH can
operate as either a potent facilitator or inhibitor of cellular proliferation
dependent on context; though in adult epithelial and vascular tissues, is
most often reported to mediate cell cycle arrest and exhibit tumour
suppressor properties [14,16–18]. Our previous studies have reported
that protein kinase CK2-dependent phosphorylation of PRH at residues
Ser163 and Ser177 abrogates DNA-binding potential and transcriptional
regulation activity, reduces nuclear retention and lowers stability via
directing PRH for proteasome-mediated proteolysis [19,20]. By this
action, CK2 alleviates PRH-mediated suppression of cell cycle pro-
gression in human leukaemic myeloid K562 cells [19]. We hypothesize
therefore that inhibition of CK2 leads to suppression of VSMC pro-
liferation via PRH. This hypothesis contradicts what was postulated by
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Sekiguchi and colleagues, where it was proposed that PRH facilitates
neointima formation by participating in the de-diﬀerentiation of medial
VSMC [21].
2. Materials and methods
All reagents were purchased from Sigma Aldrich Corporation unless
otherwise stated.
2.1. Isolation and culture of primary rat aortic VSMCs
The housing and care of all animals was undertaken in accordance
with the guidelines and regulations of the University of Bristol and the
United Kingdom Home Oﬃce. This study conforms to the Guide for the
Care and Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication No. 85-23, revised 1996). VSMCs
were grown from thoracic and abdominal rat aorta employing the ex-
plant method described previously [22]. VSMCs were cultured in Dul-
becco's modiﬁed essential medium (DMEM; GE Healthcare) supple-
mented with 100 μg/ml penicillin and 100 IU/ml streptomycin, 2 mM
L-glutamine, 8 μg/ml gentamicin and 10% (v/v) foetal calf serum (FCS)
(PAA laboratories); cells between passages 2 and 9 were utilised for
experiments. Recombinant human platelet-derived growth factor-BB
(PDGF-BB), recombinant human basic ﬁbroblast growth factor (bFGF),
and recombinant mouse Wnt-4 were purchased from R & D Systems.
Pharmacological inhibitors of protein kinase CK2, TBB (4,5,6,7-tetra-
bromobenzotriazole) and K66 (1-carboxymethyl-2-dimethylamino-
4,5,6,7-tetrabromo-benzimidazole), were acquired from Sigma Aldrich
and Merck Millipore, respectively.
2.2. Culture of HUVECs and HSaVECs
Human umbilical vein endothelial cells (HUVECs) and human sa-
phenous vein endothelial cells (HSaVECs) were obtained from
Promocell. Cells were cultured in endothelial cell growth medium
(Promocell; C-22010) or endothelial cell basal medium (Promocell; C-
22210) supplemented with 100 μg/ml penicillin and 100 IU/ml strep-
tomycin; basal medium was additionally supplemented with 0.5–2.0%
FCS. Additional components of the complete endothelial cell growth
medium included 20 μl/ml foetal calf serum, 4 μl/ml endothelial cell
growth supplement, 0.1 ng/ml recombinant human epidermal growth
factor, 1 ng/ml recombinant human bFGF, 90 μg/ml heparin and 1 μg/
ml hydrocortisone.
2.3. Preparation and culture of human saphenous vein organ cultures and
VSMCs
To induce intima formation human saphenous vein segments were
subjected to organ culture as described previously [23]. Surplus seg-
ments of surgically prepared human saphenous vein obtained from
consenting patients (Ethics number REC: 11/SW/0154) were collected
and dissected in 25 mM Hepes-buﬀered RPMI 1640 culture medium
(Gibco) supplemented with 100 μg/ml penicillin and 100 IU/ml strep-
tomycin, 2 mM L-glutamine, 8 μg/ml gentamicin and 10% (v/v) FCS.
Adventitia was carefully removed to minimise ﬁbroblast growth, vein
opened along its longitudinal axis and transverse segments cut to yield
5–10 mm segments. Vein segments were pinned down onto mesh in
Sylgard resin-coated petri dishes and cultured in sodium bicarbonate-
buﬀered RPMI 1640 (Gibco) supplemented with 100 μg/ml penicillin
and 100 IU/ml streptomycin, 2 mM L-glutamine, 8 μg/ml gentamicin,
30% (v/v) FCS and 10 μM BrdU. Culture medium was replenished every
2–3 days. On day 14, venous material was either ﬁxed in 10% (v/v)
formalin/PBS for 24 h in preparation for embedding in paraﬃn-wax, or
subjected to protein extraction. The latter was achieved by chopping
vein segments in 100 μl of sodium dodecyl sulphate (SDS) lysis buﬀer
(50 mM Tris-HCl (pH 8), 10% (v/v) glycerol, 5% (w/v) SDS) and
keeping on ice for 30 min prior to micro-centrifuging at 14,000 g for
5 min to remove debris. VSMCs were cultured from segments of sa-
phenous vein as previously described [24].
2.4. Adenovirus-mediated gene transfer
Adenoviral constructs expressing β-galactosidase, c-myc-tagged
wild-type PRH and S163C:S177C PRH were prepared using the shuttle
vector pDC 515 (Microbix Biosystems) and made replication-deﬁcient
by site-speciﬁc FLP-mediated recombination. Viral preparations were
puriﬁed on a caesium chloride gradient and the number of plaque
forming units (pfu) per ml calculated by end point dilution in HEK293
cells. Recombinant adenoviruses were diluted in culture medium to a
ﬁnal concentration of 1 × 108 pfu/ml; regarding cultured cells, culture
medium was refreshed 18 h later. Gene transfer was validated by both
RT-qPCR and Western blotting.
2.5. Amaxa nucleofection for gene transfer and silencing
Expression vectors and small interfering RNAs (siRNAs) were in-
troduced into rat aortic VSMCs utilising a Nucleofector device and the
Amaxa Basic Nucleofector Kit for primary mammalian smooth muscle
cells (Lonza; VPI-1004) in accordance with manufacturer's instructions.
For overexpression studies, 1 × 106 cells were subjected to nucleofec-
tion with 5 μg of eGFP-encoding plasmids (control), or 2.5 μg of eGFP-
and 2.5 μg of wild-type/S163C:S177C PRH-expressing plasmids using
the Nucleofector D-033 programme. Similarly, gene silencing was
achieved through delivery of 120–480 pmol Allstars negative control
siRNAs (Qiagen; 1027281), rat/human PRH (Qiagen; SI00042056), rat
CK2α (Qiagen; SI02007180, SI02007159) or rat CK2α′ (Qiagen;
SI04730628, SI04730621) siRNAs. Signiﬁcant depletion of PRH protein
required a double knockdown, where VSMCs were Amaxa nucleofected
with 240 ng Allstars negative control siRNAs or 240 ng PRH-speciﬁc
siRNAs, incubated for 72 h in 10% FCS culture medium, before being
subjected to nucleofection again with identical conditions. Gene
transfer and silencing were validated by both RT-qPCR and Western
blotting.
2.6. Gene transfer with jet-PEI-HUVEC transfection reagent
HUVECs were seeded in ﬁbronectin (50 μg/ml)-coated wells and
incubated overnight in endothelial cell growth medium. Culture
medium was replaced with 2% (v/v) endothelial cell basal medium.
Plasmids/jetPEI-HUVEC complexes were formulated in accordance
with manufacturer's instruction such that the N/P ratio equated to 5;
HUVECs were incubated with 100 μl of the prepared plasmid/jetPEI-
HUVEC complexes for 4 h, then culture medium replaced with en-
dothelial cell growth medium. Gene transfer was validated by both RT-
qPCR and Western blotting.
2.7. Scratch wound assay
Cells grown in wells to conﬂuency were scratched using a 1 ml
pipette tip to draw an X-shaped wound, then culture medium replaced
and supplemented with 2 mM hydroxyurea to inhibit proliferation as
described previously [24]. Wound healing was allowed for 24 h and the
migrated distance measured at 20 points along the wound edge using Q-
Capture Pro Imaging software.
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2.8. Proliferation assays – BrdU incorporation and Click-iT EdU Imaging
Culture medium was supplemented with 10 μM BrdU or EdU
and incorporation quantiﬁed via immunocytochemistry/immuno-
ﬂuorescence for BrdU, or application of the Click-iT EdU Alexa Fluor
488 Imaging Kit (Molecular Probes; C10337), in accordance with
manufacturer's instructions.
2.9. Immunocytochemistry
Cells seeded on glass coverslips were ﬁxed in 3% (w/v) paraf-
ormaldehyde/PBS for 10 min and permeabilised with 0.1–1.0% (v/v)
Triton X-100/PBS. Immunocytochemistry for BrdU required DNA de-
naturation which was achieved by incubation with 2N HCl for 30 min at
37 °C. Cells were then blocked with 20% (v/v) goat serum/PBS for
30 min, and probed with primary antibody diluted in 1% (w/v) BSA/
PBS overnight at 4 °C or for 1 h at 37 °C. Primary antibodies included:
8.6 μg/ml anti-BrdU IgG (Sigma; B2531) and 1 μg/ml anti-cleaved
caspase-3 IgG (R&D Systems; MAB835). Subsequently, cells were in-
cubated with appropriate biotinylated secondary antibody diluted
1:200 in 1% (w/v) BSA/PBS for 45 min, then Dylight 488/594
Streptavidin (Vector Laboratories; SA-5488-1/SA-5594-1) or
Extravidin-HRP diluted 1:200 in 1% (w/v) BSA/PBS for 45 min.
Prolong Gold Antifade Reagent with DAPI (Molecular Probes; P36931)
was utilised for mounting, or cells were incubated with Fast DAB
Peroxidase Substrate, stained with haematoxylin and mounted in
VectaMount Permanent Mount Medium (Vector Laboratories; H-5000).
2.10. Immunohistochemistry/immunoﬂuorescence
Citric acid antigen retrieval was performed on deparaﬃnised and
rehydrated tissue. For BrdU detection DNA denaturation was achieved
by incubation with 125 U/ml benzonase, 1 mM Mg2+ in PBS for 2 h at
37 °C. Sections were blocked in either 20% (v/v) goat serum/PBS or
Image-iT FX Signal Enhancer (Molecular Probes; I36933), then probed
with primary antibodies diluted in 1% (w/v) BSA/PBS overnight at
4 °C. Primary antibodies included: 88 ng/ml anti-α-smooth muscle cell
actin IgG (Dako; M0851), 8.6 μg/ml anti-BrdU IgG (Sigma; B2531),
4 μg/ml anti-cleaved caspase-3 IgG (R&D Systems; MAB835), 22.4 ng/
ml anti-c-myc-tag IgG (Cell Signalling; 2276), 8.5 μg/ml anti-phospho-
CK2 substrate (motif pS/pTDXE) IgG (Cell Signalling; 8738), 2.5 μg/ml
anti-PRH IgG (Abcam; ab34222) and 1:1000 anti-phospho-PRH IgG (in-
house). Non-immune IgG was used as negative control. Subsequently,
sections were incubated with appropriate biotinylated secondary anti-
body diluted 1:200 in 1% (w/v) BSA/PBS for 45 min, then Dylight 488/
594 Streptavidin (Vector Laboratories; SA-5488-1/SA-5594-1) or
Extravidin-HRP diluted 1:200 in 1% (w/v) BSA/PBS for 45 min.
Prolong Gold Antifade Reagent with DAPI (Molecular Probes; P36931)
was utilised for mounting, or sections were incubated with Fast DAB
Peroxidase Substrate, stained with haematoxylin, dehydrated and
mounted in VectaMount Permanent Mount Medium (Vector
Laboratories; H-5000). Staining was quantiﬁed by calculating either the
percentage of positive cells or via pixel analysis using Image-Pro Image
software.
2.11. Histological processing
Formalin-ﬁxed human saphenous vein organ cultures were trans-
ferred to PBS, then subsequently process and embedded in paraﬃn wax
using the Shandon Excelsior Tissue Processor (Thermo Electron
Corporation). Section of 3 μm thickness were cut on a microtome and
dried onto Superfrost Plus Microscope Slides (Thermo Scientiﬁc;
J1800AMNZ).
2.12. Western blotting
Cells were lysed in SDS lysis buﬀer (50 mM Tris-HCl (pH 8), 10%
(v/v) glycerol, 5% (w/v) SDS) and protein concentrations calculated
using the Micro Bicinchoninic Acid (BCA) Assay Kit (Thermo Scientiﬁc;
23235) in accordance with manufacturer's instructions. Western blot-
ting was performed using the Bio-Rad Mini Format 1-D Electrophoresis
System. One volume Laemmli Sample Buﬀer (Bio-Rad; 161-0737) with
5% (v/v) β-mercaptoethanol was added to 5-10 μl of lysate, for which
protein concentration was normalised with HPLC water. Samples and
BLUeye Prestained Protein Ladder (Geneﬂow; S6-0024) were heated at
95 °C for 5 min before loading onto Mini-PROTEAN TGX Gels (Bio-Rad;
456-1084) or Mini-PROTEAN TGX Stain-Free Gels (Bio-Rad; 456-8084),
and being electrophoresed in 1× Tris/Glycine/SDS running buﬀer
(Bio-Rad; 161-0772) at 300 V for 20 min. Protein was normalised
against either β-actin or in-gel stain-free bands visualised via a 5 min
exposure to UV light. Protein was then transferred to Trans‑Blot
Mini/Midi Nitrocellulose Membranes (Bio-Rad; 170-4158/170-4150)
using the Trans-Blot Turbo Transfer Starter System (Bio-Rad;
170-4155).
Nitrocellulose membranes were blocked in 5% fat-free milk
powder/TBST (20 mM Tris, 137 mM NaCl, 0.1% (v/v) Tween 20;
pH 7.6), incubated overnight at 4 °C with diluted primary antibody,
washed with TBST, probed with appropriate HRP-conjugated secondary
antibody, and washed with TBST before signal detection with Luminata
Forte Western HRP substrate (Merck Millipore; WBLUF0100). Primary
antibodies included: 0.11 μg/ml anti-β-actin IgG (Sigma; A5316),
20 ng/ml anti-CK2α IgG (Cell Signalling; 2656), 1:500 anti-CK2α’ IgG
(Abcam; ab135245), 0.85 μg/ml anti-phospho-CK2 substrate (motif pS/
pTDXE) IgG (Cell Signalling; 8738), 0.25 μg/ml anti-PRH IgG (Abcam;
ab34222) and 1:2000 anti-phospho-PRH IgG (in-house).
2.13. Statistics
Data were analysed by Student t-tests for two groups, or ANOVA and
Student-Newman-Keuls Multiple Comparisons post hoc test was utilised
for more than two group analyses. The experiments were repeated 3–7
times with diﬀerent batches of cells or samples of tissue, and ﬁndings
were considered statistically signiﬁcant when p < 0.05.
3. Results
3.1. Pharmacological inhibition of protein kinase CK2 retarded VSMC
proliferation in vitro
Primary cultures of rat aortic VSMCs were serum-starved for 72 h,
then quiescent cells stimulated with 20 ng/ml recombinant human
PDGF-BB and 20 ng/ml recombinant human bFGF, or 500 ng/ml re-
combinant mouse Wnt-4, or serum-starved for a further 24 h.
Concurrently, cells were treated with 0.1% DMSO vehicle control or
synthetic CK2 inhibitors - 1 μM TBB (4,5,6,7-tetrabromobenzotriazole)
or 10 μM K66 (1-carboxymethyl-2-dimethylamino-4,5,6,7-tetrabromo-
benzimidazole) in 0.1% DMSO. Both compounds have low promiscuity
and high eﬃcacy at the applied concentrations [25]. As assessed by
quantifying BrdU incorporation, inhibition of CK2 with K66 sig-
niﬁcantly suppressed VSMC proliferation, with the rate of cell replica-
tion reduced to basal rates while TBB only did this with Wnt4 stimu-
lated cells (Fig. 1A and B). K66 was a more potent anti-proliferative
agent than TBB (PDGF-BB & bFGF; 53.8 ± 0.8% inhibition vs.
33.2 ± 7.1%, p < 0.05). To validate activation of CK2 in response to
a growth stimulus, quiescent human saphenous vein VSMCs were
treated with 20 ng/ml recombinant human PDGF-BB and 20 ng/ml
recombinant human bFGF, or serum-starved, for 24 h; Western blotting
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was subsequently performed for proteins containing a pS/pTDXE motif,
a CK2 phosphorylation consensus sequence. Phosphorylation of CK2
substrates was signiﬁcantly elevated in response to PDGF-BB and bFGF
stimulation (2.6 ± 0.3-fold induction, p < 0.05), demonstrating ac-
tivation of protein kinase CK2 (Fig. 1C). K66 also impaired cell cycle
progression in isolated human saphenous vein VSMCs: quiescent cells
were stimulated with 20 ng/ml recombinant human PDGF-BB and
20 ng/ml recombinant human bFGF in the presence of 10 μM K66 or
0.1% DMSO, and cell replication monitored by quantiﬁcation of EdU
incorporation for 24 h (Fig. 1D). These data suggest that the action of
K66 is not species-speciﬁc. Scratch wounds assays and im-
munocytochemistry for cleaved caspase-3 indicated that K66 did not
inﬂuence cell migration (Fig. 1E) or viability (Fig. 1F) in rat aortic
VSMCs. Additionally, siRNA-mediated silencing of CK2 α and α’ cata-
lytic subunits suppressed VSMC proliferation (Fig. 1G).
Fig. 1. Inhibition and silencing of protein kinase CK2 reduced proliferation of cultured VSMCs. Quiesced rat aortic VSMCs were stimulated with either 20 ng/ml PDGF-BB and 20 ng/ml
bFGF, or 500 ng/ml Wnt-4, or remained serum-starved, in the presence of a CK2 inhibitor (a, 1 μM TBB; b, 10 μM K66) or vehicle control (0.1% DMSO). Proliferation was assessed by
quantiﬁcation of BrdU incorporation after 24 h. * indicates signiﬁcant diﬀerence compared to serum-starved – 0.1% DMSO, n = 3. † indicates signiﬁcant diﬀerence compared to PDGF &
bFGF – 0.1% DMSO, n = 3. ‡ indicates signiﬁcant diﬀerence compared to Wnt-4 – 0.1% DMSO, n = 3. $ indicates signiﬁcant diﬀerence compared to serum-starved – 0.1% DMSO and
serum-starved - 1 μM TBB/10 μM K66, n = 3, p < 0.05, ANOVA and Student Newman Keuls post hoc test. c, Quiesced human saphenous vein VSMCs were stimulated with 20 ng/ml
PDGF-BB and 20 ng/ml bFGF, or serum starved, for 24 h. Representative Western blot for CK2 substrates with a consensus pS/pTDXE motif, n = 3. Grey arrows indicate quantiﬁed bands.
d, Quiesced human saphenous vein VSMCs were stimulated with 20 ng/ml PDGF-BB and 20 ng/ml bFGF in the presence of 10 μM K66 or 0.1% DMSO, and proliferation assessed by
quantiﬁcation of EdU incorporation after 24 h. * indicates signiﬁcant diﬀerence compared to 0.1% DMSO, n = 5, p < 0.05, Students t-test. e, Quantiﬁcation of migration using the
scratch wound assay in VSMCs cultured in the presence of CK2 inhibitor (10 μM K66) or vehicle control (0.1% DMSO), n = 4. f, Rat aortic VSMCs were stimulated with 20 ng/ml PDGF-
BB and 20 ng/ml bFGF in the presence of 10 μM K66 or 0.1% DMSO for 24 h and then immunocytochemistry for cleaved caspase-3 performed to quantify apoptosis. 200 ng/ml Fas ligand
was used a positive control. * indicates signiﬁcant diﬀerence compared to serum-starved control, n = 5, p < 0.05, ANOVA and Student Newman Keuls post hoc test. NS denotes not
signiﬁcant. g, Quiesced rat aortic VSMCs were subjected to nucleofection with either Allstars negative control, or CK2α & α’ siRNAs, then stimulated with both 20 ng/ml PDGF-BB and
20 ng/ml bFGF. Proliferation was assessed via quantiﬁcation of BrdU incorporation between 48 and 72 h post-introduction of siRNAs. * indicates signiﬁcant diﬀerence compared to
Allstars Negative Control, n = 3, p < 0.05, Students t-test. Western blots show validation of silencing of CK2α & α′ catalytic subunits, representative of n = 3.
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3.2. PRH antagonised VSMC proliferation in vitro
To determine the function of PRH in the context of VSMC pro-
liferation, primary cultures of rat aortic VSMCs were subjected to ec-
topic overexpression or knockdown of PRH, then subsequent quantiﬁ-
cation of BrdU incorporation was performed. Introduction of PRH
expression vectors via Amaxa nucleofection antagonised cell prolifera-
tion compared to eGFP-transfected cells (Fig. 2A). To achieve reduced
(by 45 ± 8%, n = 3) expression of PRH double nucleofection of siRNA
was required 72 h apart (Fig. 2B). The double nucleofection protocol
using control Allstars siRNA reduced the rate of proliferation in re-
sponse to PDGF-BB and bFGF to approximately 8% (Fig. 2B), this is
lower than observed with single transfection (~20%, n = 3, Fig. 1A, B
and G). SiRNA-induced silencing of PRH promoted cell replication
(Fig. 2B). Together this demonstrated that PRH exerts an anti-pro-
liferative action in cultured rat aortic VSMCs. Immunocytochemistry for
cleaved caspase-3 demonstrated that PRH did not inﬂuence apoptotic
cell turnover (Fig. 2C).
Previous studies have reported that mutation of Ser163 and Ser177
within the PRH homeodomain to cysteine residues is preventative of
CK2-mediated phosphorylation, preserving DNA-binding potential,
transcriptional regulation activity, nuclear retention and protein
stability [19,20]. To evaluate whether S163C:S177C PRH presents
elevated or prolonged growth-inhibitory properties, cultured
VSMCs were Amaxa nucleofected with wild-type or S163C:S177C PRH-
encoding plasmids and proliferation monitored between 24 and
96 h post-nucleofection: up to 48 h, S163C:S177C PRH displayed a
parallel anti-mitotic eﬀect to wild-type PRH; though, unlike
wild-type, exhibited the capacity to suppress cell division for up to
96 h (Fig. 2D).
3.3. Protein kinase CK2 promoted VSMC proliferation via a PRH-dependent
mechanism in vitro
Primary cultures of rat aortic VSMCs were subjected to Amaxa nu-
cleofection with PRH speciﬁc siRNAs, and subsequently treated with
either 0.1% DMSO vehicle control or 10 μM K66 in 0.1% DMSO for
24 h. Treatment with K66 markedly attenuated the proliferative rate of
cells transfected with negative control siRNAs, but its eﬃcacy was lost
in cells subjected to PRH silencing (Fig. 2B). These data highlight the
salience of the CK2-PRH signalling axis in VSMC mitogenic signal
transduction.
Fig. 2. PRH inhibited VSMC proliferation. a, Quiescent rat aortic VSMCs were nucleofected with either eGFP, or eGFP and wild-type PRH expression vectors – co-transfection with eGFP
enabled identiﬁcation of cells expressing the transgene. Cells were stimulated with 10% FCS culture medium and proliferation assessed via quantiﬁcation of BrdU incorporation between
24 and 48 h post-transfection. * indicates signiﬁcant diﬀerence compared to eGFP, n = 7, p < 0.05, Students t-test. b, Serum-starved rat aortic VSMCs were subjected to nucleofection
with either Allstars negative control or PRH siRNAs; cells were nucleofected twice, 72 h apart, to achieve signiﬁcant depletion of PRH protein. Cells were stimulated with 20 ng/ml PDGF-
BB and 20 ng/ml bFGF, and proliferation was assessed between 48 and 72 h post-transfection in the presence of either DMSO (vehicle control) or 10 μM K66. * indicates signiﬁcant
diﬀerence compared to Allstars Neg. Control - DMSO, † indicates signiﬁcant diﬀerence compared to Allstars Neg. Control - 10 μM K66, n = 3, p < 0.05, ANOVA and Student Newman
Keuls post hoc test. NS denotes not signiﬁcant. Western blot shows validation of silencing of PRH, representative of n = 3. c, Quantiﬁcation of apoptosis by immunoﬂuorescence for
cleaved caspase-3 48 h post-introduction of either eGFP, or eGFP and wild-type PRH expression vectors in rat aortic VSMCs. Fas ligand was used as a positive control. * indicates
signiﬁcant diﬀerence compared to eGFP and eGFP + wild-type PRH, n = 3, p < 0.05, ANOVA and Student Newman Keuls post hoc test. NS denotes not signiﬁcant. d, Asynchronous rat
aortic VSMCs over-expressing either wild-type PRH or S163C:S177C PRH were stimulated with 10% FCS culture medium, and proliferation quantiﬁed over a 96-h time course. * indicates
signiﬁcant diﬀerence compared to eGFP within the same time-frame, n = 3, p < 0.05, ANOVA and Student Newman Keuls post hoc test.
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3.4. Protein kinase CK2 and PRH in cultured endothelial cells
Thrombotic occlusion, intimal hyperplasia and atherosclerotic
plaque development are direct consequences of endothelial dysfunc-
tion. In designing interventions to impair restenosis, one must consider
whether the approach is detrimental to endothelial function or pre-
ventative of post-operative re-endothelialisation so as to not exacerbate
disease progression. As inhibition of protein kinase CK2 and over-
expression of PRH presented as viable antagonists of VSMC replication,
and thus show potential for impairing neointima formation in a clinical
setting, the risk of any adverse eﬀects to the endothelium was eval-
uated. In both HUVECs (data not shown) and HSaVECs, treatment with
10 μM K66 marginally disrupted cell cycle progression yet did not in-
ﬂuence apoptosis or migration as assessed by quantifying BrdU/EdU
incorporation, immunoﬂuorescence for cleaved caspase-3 and scratch
wound assays, respectively (Fig. 3A–C). Introduction of PRH expression
constructs via use of jetPEI-HUVEC transfection reagent or adenovirus-
mediated delivery also did not signiﬁcantly aﬀect proliferation, apop-
tosis or migration (Fig. 3D–F).
3.5. CK2 inhibition impaired neointima formation ex vivo
Human saphenous vein organ cultures are a well-established model
of neointima development which can be used for testing novel
Fig. 3. Eﬀect of inhibition of protein kinase CK2 and overexpression of PRH on proliferation and apoptosis of HSaVECs. HSaVECs were cultured in endothelial cell growth medium. a,
Quantiﬁcation of proliferation by ﬂuorescent labelling of incorporated EdU in HSaVECs treated with CK2 inhibitor (10 μM K66) or vehicle control (0.1% DMSO) for 24 h. * indicates
signiﬁcant diﬀerence compared to 0.1% DMSO, n = 3, p < 0.05, Students t-test. b, Quantiﬁcation of apoptosis by immunocytochemistry for cleaved caspase-3 in HSaVECs treated with
10 μM K66 or 0.1% DMSO for 24 h. Fas ligand was used as a positive control. * indicates signiﬁcant diﬀerence compared to 0.1% DMSO and 10 μM K66, n = 3, p < 0.05, ANOVA and
Student Newman Keuls post hoc test. NS denotes not signiﬁcant. c, Migration was quantiﬁed by scratch wound assay in HSaVECs treated with 10 μM K66 or 0.1% DMSO for 24 h. NS
denotes not signiﬁcant, n = 3. Quantiﬁcation of proliferation by ﬂuorescent labelling of incorporated EdU (d), apoptosis by immunocytochemistry for cleaved caspase-3 (e) or migration
by scratch wound assay (f) in HSaVECs overexpressing PRH, n = 3. NS denotes not signiﬁcant, Students t-test.
Fig. 4. Enhanced CK2 activity as a result of neointima formation. Segments of human saphenous vein were subjected to organ for 0 or 14 days, n = 6, and subjected to immuno-
ﬂuorescence for phosphorylated CK2 substrates. a, vein segment at day 0 incubated with anti-phosphorylated CK2 substrate antibody, b, segment after 14 days of cultured incubated with
anti-phosphorylated CK2 substrate antibody. c, segment after 14 days of cultured incubated with non-immune rabbit IgG (negative control). Phosphorylated CK2 protein (green) and
nuclei are blue (DAPI). Scale bars represents 10 μm and apply to all panels. Dashed lines indicate intimal:medial boundaries. (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the web version of this article.)
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Fig. 5. Treatment of human saphenous organ cultures with
10 μM K66 retarded neointima formation. Segments of
human saphenous vein were subjected to organ culture in
the presence of BrdU, and 10 μM K66 or vehicle control
(0.1% DMSO) for 14 days, n = 6. a, EVG-stained sections of
human saphenous vein organ cultures. b,
Immunohistochemistry for intimal (upper panels) and
medial (lower panels) α-smooth muscle cell actin (brown).
c, Proliferation detected by immunoﬂuorescence for in-
corporated BrdU (green). Nuclei are blue (DAPI) in lower
panels. Arrows indicate positive cells. Scale bars represents
10 μm and apply to all panels. Dashed lines indicate in-
timal:medial boundaries. (For interpretation of the refer-
ences to colour in this ﬁgure legend, the reader is referred
to the web version of this article.)
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therapeutic interventions. Culture of saphenous vein for 14 days en-
hanced the amount of phosphorylated CK2 substrates, indicating en-
hanced CK2 activity (Fig. 4). Intact venous material was cultured for
14 days in the presence or absence of 0.1% DMSO vehicle control or
10 μM K66. Treatment with K66 dramatically reduced the average in-
timal thickness with respect to control (Fig. 5A and Table 1). No dif-
ference in neointimal cell or VSMC density was observed between
control and treated samples (Fig. 4B and Table 1). K66 signiﬁcantly
decreased medial α-smooth muscle cell actin density (Fig. 5B and
Table 1). Culture of human saphenous vein for 14 days causes an in-
crease in α-smooth muscle cell actin density due to VSMC proliferation
(day 14 vs. day 0, 11.5 ± 1.0 vs. 9.5 ± 1.0%, respectively). Inter-
estingly, K66 suppressed this increase at day 14, and as a consequence
the medial α-smooth muscle cell actin density was comparable to basal
levels at day 0. Consequently, the decrease in α-smooth muscle cell
actin density as a result of K66 result edin a similar density of VSMCs in
the media as at day 0, and is unlikely therefore to lead to an adverse
eﬀect on vessel function. Quantiﬁcation of BrdU incorporation de-
monstrated signiﬁcant suppression of neointimal (Fig. 5C) and medial
mitotic activity with K66 treatment though no response with regards to
migratory activity (number of BrdU-negative cells per mm of neoin-
tima) was observed (Table 1). Immunoﬂuorescence for cleaved caspase-
3 revealed that the rate of apoptosis was extremely low and this was
unaﬀected by the presence of K66. Both immunostaining of sections
and Western blotting on whole tissues lysates identiﬁed an up-regula-
tion in neointimal and total PRH protein expression in K66-treated
material compared to control, respectively (Fig. 6A, C–D and Table 1).
Histological staining further demonstrated a depletion of phospho-PRH
protein in saphenous vein material treated with K66 suggesting eﬀec-
tive inhibition of protein kinase CK2 (Fig. 6B and Table 1). In ac-
cordance with this, primary cultures of isolated human saphenous vein
VSMCs were serum-starved for 72 h, then stimulated with 20 ng/ml
recombinant human PDGF-BB and 20 ng/ml recombinant human bFGF
for 24 h in the presence of either 10 μM K66 or 0.1% DMSO: Western
blotting indicated a reduction in phospho-PRH protein in K66-treated
samples (Fig. 6E–F).
3.6. Adenovirus-mediated delivery of PRH impaired neointima formation ex
vivo
Intact segments of human saphenous vein were either uninfected or
infected with β-galactosidase or c-myc-tagged S163C:S177C PRH-en-
coding vectors on days 0, 5, and 10 of a 14 day culture. Immunostaining
for c-myc-tagged protein conﬁrmed expression of c-myc-tagged
S163C:S177C PRH at the luminal surface (Fig. 7B). Introduction of the
S163C:S177C PRH transgene signiﬁcantly reduced neointima formation
with respect to uninfected control or venous material infected with β-
galactosidase-encoding recombinant adenoviruses (Fig. 7A and
Table 2). Neointimal cell or VSMC density was not aﬀected by the in-
troduction of the S163C:S177C PRH transgene (Fig. 7C and Table 2).
Quantiﬁcation of BrdU incorporation indicated a marked reduction in
the percentage of proliferative, neointimal cells in vein segments in-
fected with adenovirus expressing S163C:S177C PRH compared to
controls (Fig. 7D and Table 2), though no inﬂuence on migration was
observed (Table 2). Immunoﬂuorescence for cleaved caspase-3 revealed
no eﬀect on apoptotic rate.
4. Discussion
Neointimal VSMC accumulation contributes considerably to vessel
occlusion observed in both autologous vein graft degeneration [1,2]
and in-stent restenosis [26,27]. In this study, the potential for retarding
VSMC proliferation and hence ameliorating pathophysiological neoin-
tima formation via manipulation of the CK2-PRH signalling axis was
evaluated. Utilising appropriate strategies for delivery of synthetic CK2
inhibitors may be of beneﬁt to patients receiving vein grafts or drug-
eluting stents.
Induction of VSMC proliferation with PDGF-BB and bFGF and cul-
ture of saphenous vein for 14 days led to enhanced CK2 activity (de-
tected with anti-phosphorylated CK2 substrate antibody).
Pharmacological inhibition of protein kinase CK2 with the synthetic
compounds TBB and K66 signiﬁcantly reduced proliferation in isolated
VSMCs. The K66 compound was favoured for its putative low pro-
miscuity and hence selected for the remainder of this study. The spe-
ciﬁcity of the K66 eﬀect was supported by the observation that siRNA-
induced silencing of the catalytic subunits of CK2 displayed comparable
eﬃcacy. Inhibition of CK2 activity via administration of K66 did not
aﬀect either VSMC apoptosis or migration. Importantly, K66 reduced
levels of phosphorylated PRH protein and siRNA-mediated knockdown
of PRH in K66-treated cultured VSMCs demonstrated that the anti-
proliferative action of K66 required the presence of PRH. This suggests
that phosphorylation and degradation of PRH are prerequisites for the
growth-permissive eﬀects of protein kinase CK2, as observed in human
myeloid leukaemia K562 cells [19].
The multifunctional transcription factor PRH has been previously
identiﬁed as a critical modulator of cell cycle progression, diﬀerentia-
tion and development [14], but its role in regulation of VSMC pro-
liferation and neointima formation was not fully elucidated. Sekiguchi
et al. postulated that PRH may operate as a pathogenic factor by fa-
cilitating VSMC de-diﬀerentiation as its expression was induced with
intimal thickening in conjunction with a molecular marker for de-dif-
ferentiated, synthetic VSMCs [21]. In spite of this accumulation of PRH
protein within the intima in vivo, our in vitro studies indicated that
PRH did not facilitate cell cycle progression, but in fact revealed an
anti-proliferative role for PRH. Most interestingly, the S163C:S177C
PRH mutant displayed a prolonged anti-mitotic eﬀect with respect to
wild-type PRH. To clarify, mutation of the Ser163 and Ser177 residues
within the PRH homeodomain is preventative of CK2-dependent
phosphorylation, where phosphorylation abrogates DNA-binding po-
tential and transcriptional regulation activity, reduces nuclear retention
and decreases stability via proteolysis [19,20]. Consequently, the
S163C:S177C PRH mutant possesses enhanced stability [19], which is
most likely the cause of the increased longevity of its anti-proliferative
eﬀect.
To ascertain whether interference with protein kinase CK2 activity
or PRH expression would exacerbate endothelial dysfunction, HUVECs
and HSaVECs were subjected to treatment with K66 or ectopic over-
expression of PRH. K66 moderately retarded cell cycle progression
Table 1
Human saphenous vein organ cultures treated with 0.1% DMSO vehicle control or
10 μM K66.
Parameter 0.1% DMSO 10 μM K66
Neointimal thickness/μm 39.5 ± 5.3 15.7 ± 3.5a
Cell density/cells/mm2 1211 ± 217 1524 ± 81
Neointimal αSMC actin density/% 48.9 ± 5.3 48.3 ± 5.1
Medial αSMC actin density/% 11.2 ± 1.5 9.8 ± 1.6a
Intimal proliferation/% BrdU-positive 64.9 ± 1.2 37.3 ± 1.6a
Medial proliferation/% BrdU-positive 6.3 ± 1.8 2.5 ± 1.3a
Migration/BrdU-negative cells/mm 16.8 ± 2.7 16.5 ± 1.6
Neointimal PRH protein/% PRH-positive 36.6 ± 6.1 60.4 ± 7.4a
Neointimal phospho-PRH protein/% phospho-
PRH-positive
13.2 ± 2.2 9.1 ± 1.6a
a Statistically signiﬁcant compared to 0.1% DMSO, n = 6, p < 0.05, Students t-test.
SMC; smooth muscle cell.
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without inﬂuencing cell survival and migration, whilst proliferation,
migration and cell survival were unaﬀected by PRH gene transfer. This
implies that K66 and PRH have very little eﬀect on endothelial cell
behaviour.
As demonstrated by Soyombo and colleagues [28], neointima for-
mation is a phenomenon that can be successfully replicated in ex vivo
human saphenous vein organ cultures, which is therefore a valuable
technique for the testing of novel therapeutic interventions. Utilising
this model, we demonstrated that K66 and adenovirus-mediated gene
transfer of S163C:S177C PRH signiﬁcantly retarded neointima forma-
tion. In both cases, this was exclusively attributed to their anti-
proliferative activity as migration and cell viability were unaﬀected.
Moreover, as expected, inhibition of protein kinase CK2 with K66 was
associated with elevated PRH protein but decreased phosphorylated
PRH levels in the saphenous vein organ cultures. This provides further
support that CK2 regulates PRH protein levels and activity.
Regarding further translational aspirations, as protein kinase CK2 is
ubiquitously expressed, systemic delivery of K66 would most likely
result in undesirable oﬀ target side eﬀects. Perivascular drug delivery
systems may be employed for localised, sustained release of the K66
compound to a vascular graft. Sanders and colleagues [29], reported
that delivery of anti-proliferative agents such as sunitinib – a multi-
Fig. 6. Accumulation of PRH and depletion of phospho-PRH in human saphenous vein organ cultures treated with 10 μM K66. Segments of human saphenous vein were subjected to
organ culture in the presence of either 10 μM K66 or vehicle control (0.1% DMSO) for 14 days. a, Immunoﬂuorescence for PRH protein (green). Nuclei are blue (DAPI) in lower panels.
Arrows indicate positive cells. b, Immunohistochemistry for phospho-PRH protein (brown). Nuclei are-blue (haematoxylin). Scale bars represent 10 μm and apply to all panels. Dashed
lines indicate intimal:medial boundaries. c, Quantiﬁcation of PRH protein in whole tissue lysates by Western blotting; normalisation by β-actin. * indicates signiﬁcant diﬀerence
compared to 0.1% DMSO, n = 5, p < 0.05, one sample t-test. d, Representative Western blot for PRH protein in whole tissue lysates. e, Quiesced human saphenous vein VSMCs were
stimulated with 20 ng/ml PDGF-BB and 20 ng/ml bFGF for 24 h in the presence of either 10 μM K66 or 0.1% DMSO. Representative Western blot for phospho-PRH protein. f,
Quantiﬁcation of phospho-PRH protein by Western blotting; normalisation by in-gel stain-free band. * indicates signiﬁcant diﬀerence compared to 0.1% DMSO, n = 3, p < 0.05, one
sample t-test. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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target receptor tyrosine kinase inhibitor – to porcine jugular veins could
be achieved through application of a biocompatible hyaluronic acid-
based hydrogel contained in a polyactide-co-glycolide perivascular
wrap to impede drug diﬀusion into non-target extravascular tissue.
Alternative drug delivery strategies include the use of drug-eluting
nanoparticles or even drug-linked antibodies for direct administration
of a compound to a target tissue [30]. The approaches discussed may all
be considered for localised, sustained delivery of K66 to a grafted
vasculature to prolong its patency.
To conclude, in this study, PRH has been identiﬁed as a novel in-
hibitor of VSMC proliferation; and its upstream regulator, protein ki-
nase CK2, has additionally been documented to inﬂuence cell cycle
progression. Inhibition of CK2 activity with the synthetic compound
K66 and adenovirus-mediated ectopic overexpression of S163C:S177C
PRH disrupted neointima development in human saphenous vein organ
cultures. Progression into pre-clinical research may reveal the merit of
such strategies in ameliorating saphenous vein graft stenosis and rest-
enosis after stent implantation.
Fig. 7. Adenovirus-mediated gene transfer of S163C:S177C PRH retarded neointima formation. Segments of human saphenous vein were subjected to organ culture in the presence of
BrdU, with or without infection with Ad-β-galactosidase or Ad-c-myc-tagged-S163CS177C-PRH for 14 days, n = 5. a, EVG-stained sections of human saphenous vein organ cultures. b,
Immunohistochemistry for c-myc-tagged protein (brown). c, Immunohistochemistry for α-smooth muscle cell actin (brown). d, Immunoﬂuorescence for incorporated BrdU (green).
Nuclei are blue (DAPI) in lower panels. Scale bars represents 10 μm and apply to all panels. Dashed lines indicate intimal:medial boundaries. Arrows indicate positive cells. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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Table 2
Human saphenous vein organ cultures either uninfected or subjected to infection with
adenoviruses encoding.
Parameter Uninfected β-galactosidase S163C:S177C PRH
Neointimal thickness/μm 10.7 ± 1.2 12.5 ± 2.1 4.2 ± 0.9a
Cell density/cells/mm2 2308 ± 474 2319 ± 770 2765 ± 726
intimal αSMC actin
density/%
48.4 ± 2.8 47.7 ± 3.2 46.9 ± 3.5
medial αSMC actin
density/%
12.3 ± 1.4 11.3 ± 1.7 11.4 ± 1.5
intimal proliferation/%
BrdU-positive
73.7 ± 5.0 70.2 ± 6.3 49.0 ± 5.7a
medial proliferation/%
BrdU-positive
33.4 ± 9.5 32.6 ± 10.9 39.4 ± 11.9
migration/BrdU-negative
cells/mm
5.4 ± 0.7 6.4 ± 0.9 6.1 ± 0.8
β-galactosidase or S163C:S177C PRH.
a Statistically signiﬁcant compared to 0.1% DMSO, n = 5, p < 0.05, Students t-test.
SMC; smooth muscle cell.
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